What top creators are saying about Tempus AI, Inc.(TEM)
Technology company advancing precision medicine through AI
5 AI-extracted insights from 4 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Based on 1 scored insight about Tempus AI, Inc..
The Take
Recent commentary on Tempus AI, Inc. (TEM) is universally bullish (3 of 3 sources), driven by its positioning at the intersection of AI, biotech, and high-value clinical data partnerships. Sources highlight the company as a strong growth and acquisition candidate.
Bull Case
- Acquisition appeal: Viewed as an attractive long candidate due to potential acquisition interest from major technology firms seeking proprietary clinical data pipelines (per threadguy).
- Moderna partnership: Gained 15% to 18% as a secondary beneficiary stemming from its genomic data and precision medicine partnership with Moderna (per Amit Kukreja).
- Growth optionality: Identified as an appealing asymmetric biotech and AI growth candidate suited for out-of-the-money call option strategies (per threadguy).
Catalysts & Targets
- Recent 15% to 18% gain driven by the Moderna precision medicine partnership.
AI-generated summary. Not investment advice. Learn more.
Top creators covering Tempus AI, Inc. (TEM)
The 4 sources with the most insights about Tempus AI, Inc. on Kazuha.
Latest insights about Tempus AI, Inc. (TEM)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Thursday, September 17, 2026
Identified as an attractive asymmetric biotech/AI growth candidate for out-of-the-money call option strategies.
Thursday, August 20, 2026
Attractive long candidate due to potential acquisition interest from large tech firms seeking proprietary clinical data pipelines.
Wednesday, August 19, 2026
Gained 15%–18% as a secondary beneficiary due to its genomic data and precision medicine partnership with Moderna.
Wednesday, August 12, 2026
Selected as a high-potential application-layer software beneficiary in the AI ecosystem.
Tuesday, March 24, 2026
Cited as a losing play that dropped over 25%, highlighting current volatility in the high-growth AI space.
Thursday, September 17, 2026
Identified as an attractive asymmetric biotech/AI growth candidate for out-of-the-money call option strategies.
Thursday, August 20, 2026
Attractive long candidate due to potential acquisition interest from large tech firms seeking proprietary clinical data pipelines.
Wednesday, August 19, 2026
Gained 15%–18% as a secondary beneficiary due to its genomic data and precision medicine partnership with Moderna.
Wednesday, August 12, 2026
Selected as a high-potential application-layer software beneficiary in the AI ecosystem.
Tuesday, March 24, 2026
Cited as a losing play that dropped over 25%, highlighting current volatility in the high-growth AI space.
Discussed alongside Tempus AI, Inc. (TEM)
Other assets that creators frequently mention in the same content as Tempus AI, Inc..
Frequently asked
Which podcasters and creators cover Tempus AI, Inc. (TEM) the most?
The most active sources covering Tempus AI, Inc. (TEM) on Kazuha are @notthreadguy, @amitinvesting, Real Vision Podcast Network, @quiverquant. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Tempus AI, Inc. (TEM) are on Kazuha?
Kazuha has indexed 5 AI-extracted insights about Tempus AI, Inc. (TEM) from 4 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Tempus AI, Inc. (TEM)?
Creators covering Tempus AI, Inc. (TEM) most frequently also discuss ETH, LLY, PLTR, BTC, MU. See the "Discussed alongside" section above for full asset pages.